| Assessment Status |
Rapid Review Complete |
| HTA ID |
– |
| Drug |
Tadalafil |
| Brand |
Adcirca® |
| Indication |
In adults for the treatment of pulmonary arterial hypertension (PAH) classified as World Health Organisation (WHO) Functional Class (FC) II and III, to improve exercise capacity. |
| Rapid review commissioned |
13/07/2011 |
| Rapid review completed |
21/09/2011 |
| Rapid review outcome |
Full Pharmacoeconomic Assessment Not Recommended |
| May 2014 |
In accordance with the Health Act (Pricing and Supply of Medical Goods) 2013 (section 18(4)), the HSE has requested the NCPE to re-examine the cost effectiveness of Tadalafil (Adcirca®). |
| Rapid review commissioned |
09/05/2014 |
| Rapid review completed |
23/05/2014 |
| Rapid review outcome |
Full Pharmacoeconomic Assessment Not Recommended |
